| 1 |
main protease
(931 times)
|
Molecular Biology
(153 times)
|
SARS-CoV-2 (217 times)
COVID-19 (136 times)
MD (119 times)
|
2003 A 3D model of SARS_CoV 3CL proteinase and its inhibitors design by virtual screening.
|
| 2 |
main protease of SARS-CoV-2
(25 times)
|
Biology
(7 times)
|
SARS-CoV-2 (4 times)
COVID-19 (2 times)
ARDS (1 time)
|
2020 Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach.
|
| 3 |
major protease
(7 times)
|
Biology
(1 time)
|
RdRp (3 times)
SARS-CoV-2 (2 times)
ATV (1 time)
|
2020 Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
|
| 4 |
main viral protease
(5 times)
|
Chemistry
(2 times)
|
COVID-19 (1 time)
hPTP1B (1 time)
|
2020 Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 Through a Molecular Docking Study.
|
| 5 |
main protease of the coronavirus
(3 times)
|
Biochemical Phenomena
(1 time)
|
SARS-CoV-2 (1 time)
|
2021 SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors.
|
| 6 |
main SARS-CoV-2 protease 3CLpro
(2 times)
|
Virology
(1 time)
|
COVID-19 (2 times)
SARS-CoV-2 (2 times)
|
2020 A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19.
|
| 7 |
main 3-chymotrypsin-like cysteine protease
(1 time)
|
Biotechnology
(1 time)
|
MD (1 time)
SARS-CoV-2 (1 time)
|
2020 SARS-CoV-2 Mpro inhibitors: identification of anti-SARS-CoV-2 Mpro compounds from FDA approved drugs.
|
| 8 |
main cysteine protease from SARS-CoV-2
(1 time)
|
Drug Design
(1 time)
|
---
|
2022 Perspectives on the design and discovery of alpha-ketoamide inhibitors for the treatment of novel coronavirus: where do we stand and where do we go?
|
| 9 |
main protease enzyme
(1 time)
|
Biology
(1 time)
|
---
|
2022 The Discovery of Small Allosteric and Active Site Inhibitors of the SARS-CoV-2 Main Protease via Structure-Based Virtual Screening and Biological Evaluation.
|
| 10 |
main protease monomer
(1 time)
|
Biochemistry
(1 time)
|
---
|
2020 Structural stability of the SARS-CoV-2 main protease: Can metal ions affect function?
|
| 11 |
Main Protease of Coronavirus SARS-CoV-2
(1 time)
|
Pharmacology
(1 time)
|
---
|
2020 Identification of Main Protease of Coronavirus SARS-CoV-2 (Mpro) Inhibitors from Melissa officinalis.
|
| 12 |
main protease protein
(1 time)
|
Medical Informatics
(1 time)
|
ACE2 (1 time)
ADME (1 time)
JAK2 (1 time)
|
2020 Plausible mechanisms explaining the role of cucurbitacins as potential therapeutic drugs against coronavirus 2019.
|
| 13 |
Main Proteases
(1 time)
|
Biotechnology
(1 time)
|
MD (1 time)
MM-PBSA (1 time)
NO (1 time)
|
2020 Potential of NO donor furoxan as SARS-CoV-2 main protease (Mpro) inhibitors: in silico analysis.
|
| 14 |
major protease inhibitors
(1 time)
|
|
---
|
2022 SMILES-based 2D-QSAR and similarity search for identification of potential new scaffolds for development of SARS-CoV-2 MPRO inhibitors.
|
| 15 |
Metabolite Targeting Viral Protease
(1 time)
|
Plant Physiological Phenomena
(1 time)
|
COVID-19 (1 time)
SARS-CoV-2 (1 time)
|
2021 Carvacrol, a Plant Metabolite Targeting Viral Protease (Mpro) and ACE2 in Host Cells Can Be a Possible Candidate for COVID-19.
|
| 16 |
mol, respectively as significant inhibitors of SARS-CoV-2
(1 time)
|
Virus Diseases
(1 time)
|
ADMET (1 time)
|
2021 Target-based drug discovery, ADMET profiling and bioactivity studies of antibiotics as potential inhibitors of SARS-CoV-2 main protease (Mpro).
|
| 17 |
Molecular interaction analysis of protease
(1 time)
|
Communicable Diseases
(1 time)
|
---
|
2021 Essential oils as an effective alternative for the treatment of COVID-19: Molecular interaction analysis of protease (Mpro) with pharmacokinetics and toxicological properties.
|
| 18 |
of7-(4-(N-substituted-carbamoyl-methyl)piperazin-1yl)-chalcone in comparison with ciprofloxacin againstSARS-CoV-2main protease
(1 time)
|
Pharmacology
(1 time)
|
FQs (1 time)
|
2021 In vitro inhibition and molecular docking of a new ciprofloxacin-chalcone against SARS-CoV-2 main protease.
|
| 19 |
SARS-CoV-2-main protease
(1 time)
|
Biotechnology
(1 time)
|
SARS-CoV-2 (1 time)
|
2021 Anti-HIV-drug and phyto-flavonoid combination against SARS-CoV-2: a molecular docking-simulation base assessment.
|
| 20 |
SARS-main CoV-2's protease
(1 time)
|
|
CADD (1 time)
MDS (1 time)
SBVS (1 time)
|
2023 In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations.
|
A Search Service for Abbreviation / Long Form